<DOC>
	<DOCNO>NCT01422018</DOCNO>
	<brief_summary>Purpose : To evaluate efficacy intravitreal bevacizumab ( IVB ) focal edema hard exudate secondary diabetic retinopathy . Design : Prospective interventional case series . Participants : Ten eye 10 consecutive patient show focal edema hard exudate secondary diabetic retinopathy eligible focal laser photocoagulation due central location ( &lt; 500 µm fovea ) .</brief_summary>
	<brief_title>Effect Intravitreal Bevacizumab Focal Edema With Hard Exudates Secondary Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Complications</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1. patient either gender age &gt; 18 year 2. patient type 2 diabetes 3. central macular thickness &gt; 300 µm OCT 4. eye eligible focal laser photocoagulation due central location hard exudate ( &lt; 500 µm ) 5. area retinal thickening le 2 disc area diameter 6 . 67 % leakage associate microaneurysms 1. eye history laser photocoagulation pharmacological intervention DME study eye 2. eye pharmacologic intervention fellow eye within 6 month 3. history ocular disease diabetic retinopathy 4. surgical history cataract extraction intraocular lens implantation 5. panretinal photocoagulation within 3 month enrollment 6. medium opacity 7. thromboembolic event within 6 month , evidence active cardiac ischemia electrocardiogram ( ECG ) time screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>clinically significant macular edema</keyword>
	<keyword>diabetic macular edema</keyword>
	<keyword>focal edema</keyword>
	<keyword>focal laser photocoagulation</keyword>
	<keyword>hard exudate</keyword>
	<keyword>intravitreal bevacizumab</keyword>
</DOC>